Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail
This article was originally published in Pharmaceutical Approvals Monthly
While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.
You may also be interested in...
All eyes are on Gilead Sciences following the news it may not continue development of GS-7977 alongside Bristol-Myers Squibb’s daclatasvir, though the all-oral pairing produced impressive data in Phase II.
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
Biotech says that latest data on its protease inhibitor ACH-1625 enhances its position in negotiating partnerships for the compound.